SG11201503134WA - Novel rock inhibitors - Google Patents
Novel rock inhibitorsInfo
- Publication number
- SG11201503134WA SG11201503134WA SG11201503134WA SG11201503134WA SG11201503134WA SG 11201503134W A SG11201503134W A SG 11201503134WA SG 11201503134W A SG11201503134W A SG 11201503134WA SG 11201503134W A SG11201503134W A SG 11201503134WA SG 11201503134W A SG11201503134W A SG 11201503134WA
- Authority
- SG
- Singapore
- Prior art keywords
- rock inhibitors
- novel rock
- novel
- inhibitors
- rock
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 239000011435 rock Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12190859 | 2012-10-31 | ||
| PCT/EP2013/072774 WO2014068035A1 (en) | 2012-10-31 | 2013-10-31 | Novel rock inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201503134WA true SG11201503134WA (en) | 2015-05-28 |
Family
ID=47148627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201503134WA SG11201503134WA (en) | 2012-10-31 | 2013-10-31 | Novel rock inhibitors |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9394286B2 (enExample) |
| EP (1) | EP2914590B1 (enExample) |
| JP (1) | JP6205425B2 (enExample) |
| KR (1) | KR102242280B1 (enExample) |
| CN (1) | CN104822676B (enExample) |
| AU (1) | AU2013340854B2 (enExample) |
| BR (1) | BR112015009504A2 (enExample) |
| CA (1) | CA2922312C (enExample) |
| DK (1) | DK2914590T3 (enExample) |
| EA (1) | EA026629B1 (enExample) |
| ES (1) | ES2617495T3 (enExample) |
| IL (1) | IL238391A (enExample) |
| IN (1) | IN2015DN04311A (enExample) |
| MX (1) | MX362485B (enExample) |
| NZ (1) | NZ708526A (enExample) |
| PL (1) | PL2914590T3 (enExample) |
| PT (1) | PT2914590T (enExample) |
| SG (1) | SG11201503134WA (enExample) |
| WO (1) | WO2014068035A1 (enExample) |
| ZA (1) | ZA201503544B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015196072A2 (en) | 2014-06-19 | 2015-12-23 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| WO2016172159A1 (en) * | 2015-04-20 | 2016-10-27 | University Of Houston System | Locally bioavailable drugs |
| CN106928252B (zh) * | 2015-12-31 | 2019-09-27 | 成都先导药物开发股份有限公司 | 一种抑制rock的化合物及其制备方法与应用 |
| EP3693380A1 (en) * | 2019-02-11 | 2020-08-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Dual inhibition of plexin-b1 and plexin-b2 |
| US12371667B2 (en) | 2021-05-13 | 2025-07-29 | Washington University | Enhanced methods for inducing and maintaining naive human pluripotent stem cells |
| US20250000083A1 (en) | 2021-11-11 | 2025-01-02 | The Doshisha | Cryopreservation preparation for corneal endothelial cells and method for producing said cryopreservation preparation |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7217722B2 (en) | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
| US8071779B2 (en) * | 2006-12-18 | 2011-12-06 | Inspire Pharmaceuticals, Inc. | Cytoskeletal active rho kinase inhibitor compounds, composition and use |
| US20090325960A1 (en) | 2008-06-26 | 2009-12-31 | Fulcher Emilee H | Method for treating inflammatory diseases using rho kinase inhibitor compounds |
| US8299096B2 (en) | 2008-06-26 | 2012-10-30 | Inspire Pharmaceuticals, Inc. | Method for treating pulmonary diseases using rho kinase inhibitor compounds |
| US20090325959A1 (en) | 2008-06-26 | 2009-12-31 | Vittitow Jason L | Method for treating ophthalmic diseases using rho kinase inhibitor compounds |
| EP2400969A4 (en) | 2008-12-04 | 2012-05-16 | Inspire Pharmaceuticals Inc | METHOD FOR TREATING PULMONARY DISEASES USING RHO KINASE INHIBITORY COMPOUNDS |
| EP2512239A4 (en) * | 2009-12-14 | 2014-11-26 | Inspire Pharmaceuticals Inc | BROKEN BICYCLIC RHO-KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE |
| WO2012012282A1 (en) * | 2010-07-19 | 2012-01-26 | Inspire Pharmaceuticals, Inc. | Bifunctional rho kinase inhibitor compounds, composition and use |
| BR112013001015A2 (pt) * | 2010-07-27 | 2016-05-24 | Inspire Pharmaceuticals Inc | método por tratar doenças oftálmicas que usam compostos de inibidor de cinase em formas de prodrug |
| GB201107223D0 (en) * | 2011-04-29 | 2011-06-15 | Amakem Nv | Novel rock inhibitors |
-
2013
- 2013-10-31 MX MX2015005459A patent/MX362485B/es active IP Right Grant
- 2013-10-31 ES ES13786455.9T patent/ES2617495T3/es active Active
- 2013-10-31 PT PT137864559T patent/PT2914590T/pt unknown
- 2013-10-31 CA CA2922312A patent/CA2922312C/en active Active
- 2013-10-31 DK DK13786455.9T patent/DK2914590T3/en active
- 2013-10-31 SG SG11201503134WA patent/SG11201503134WA/en unknown
- 2013-10-31 NZ NZ708526A patent/NZ708526A/en not_active IP Right Cessation
- 2013-10-31 PL PL13786455T patent/PL2914590T3/pl unknown
- 2013-10-31 IN IN4311DEN2015 patent/IN2015DN04311A/en unknown
- 2013-10-31 EA EA201590847A patent/EA026629B1/ru unknown
- 2013-10-31 JP JP2015540120A patent/JP6205425B2/ja not_active Expired - Fee Related
- 2013-10-31 BR BR112015009504A patent/BR112015009504A2/pt not_active Application Discontinuation
- 2013-10-31 US US14/437,919 patent/US9394286B2/en not_active Expired - Fee Related
- 2013-10-31 KR KR1020157014431A patent/KR102242280B1/ko not_active Expired - Fee Related
- 2013-10-31 EP EP13786455.9A patent/EP2914590B1/en active Active
- 2013-10-31 AU AU2013340854A patent/AU2013340854B2/en not_active Ceased
- 2013-10-31 CN CN201380056608.XA patent/CN104822676B/zh not_active Expired - Fee Related
- 2013-10-31 WO PCT/EP2013/072774 patent/WO2014068035A1/en not_active Ceased
-
2015
- 2015-04-20 IL IL238391A patent/IL238391A/en active IP Right Grant
- 2015-05-20 ZA ZA2015/03544A patent/ZA201503544B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP6205425B2 (ja) | 2017-09-27 |
| BR112015009504A2 (pt) | 2017-07-04 |
| CN104822676B (zh) | 2019-11-05 |
| PL2914590T3 (pl) | 2017-06-30 |
| WO2014068035A1 (en) | 2014-05-08 |
| CA2922312C (en) | 2020-10-20 |
| KR102242280B1 (ko) | 2021-04-20 |
| IN2015DN04311A (enExample) | 2015-10-16 |
| PT2914590T (pt) | 2017-02-27 |
| US9394286B2 (en) | 2016-07-19 |
| IL238391A0 (en) | 2015-06-30 |
| HK1213550A1 (zh) | 2016-07-08 |
| EA201590847A1 (ru) | 2015-08-31 |
| EP2914590A1 (en) | 2015-09-09 |
| NZ708526A (en) | 2018-08-31 |
| ZA201503544B (en) | 2017-09-27 |
| EP2914590B1 (en) | 2016-11-30 |
| CN104822676A (zh) | 2015-08-05 |
| AU2013340854B2 (en) | 2017-06-08 |
| DK2914590T3 (en) | 2017-03-06 |
| MX2015005459A (es) | 2015-07-21 |
| ES2617495T3 (es) | 2017-06-19 |
| KR20150084027A (ko) | 2015-07-21 |
| MX362485B (es) | 2019-01-21 |
| CA2922312A1 (en) | 2014-05-08 |
| IL238391A (en) | 2017-08-31 |
| AU2013340854A1 (en) | 2015-06-11 |
| US20150299173A1 (en) | 2015-10-22 |
| JP2015535270A (ja) | 2015-12-10 |
| EA026629B1 (ru) | 2017-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2519420B (en) | Electrofracturing formations | |
| ZA201504200B (en) | Beta-lactamase inhibitors | |
| ZA201503041B (en) | Gdf-8 inhibitors | |
| SG10201704095UA (en) | Dna-pk inhibitors | |
| PT2892889T (pt) | Compostos inibidores | |
| ZA201307496B (en) | Novel rock inhibitors | |
| ZA201401416B (en) | Novel rock kinase inhibitors | |
| ZA201503544B (en) | Novel rock inhibitors | |
| ZA201407904B (en) | Nampt inhibitors | |
| GB201018996D0 (en) | Novel ROCK inhibitors | |
| PL2628572T3 (pl) | Dłuto | |
| IL235919A0 (en) | inhibitors of fbxo3 | |
| PT2912021T (pt) | Inibidores de agrecanase | |
| GB201114854D0 (en) | Novel rock inhibitors | |
| GB201211019D0 (en) | Inhibitor compounds | |
| GB201003395D0 (en) | Novel rock inhibitors | |
| GB201223308D0 (en) | Enzyme inhibitors | |
| GB201104399D0 (en) | Novel inhibitors | |
| GB201219306D0 (en) | Nampt inhibitors |